0
Sign In  | Subscribe
18 November 2003, Vol 139, No. 10>
Summaries for Patients | 18 November 2003

Importance of Routinely Taking Drug Therapy for HIV-1 Infection FREE

[+] Article and Author Information

The summary below is from the full report titled “Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 × 109 cells/L.” It is in the 18 November 2003 issue of Annals of Internal Medicine (volume 139, pages 810-816). The authors are E. Wood, R.S. Hogg, B. Yip, P.R. Harrigan, M.V. O'Shaughnessy, and J.S.G. Montaner.


Ann Intern Med. 2003;139(10):I-20. doi:10.7326/0003-4819-139-10-200311180-00003
Text Size: A A A

What is the problem and what is known about it so far?

HIV-1 infection is a serious chronic illness caused by a virus. The virus attacks the body's immune system and interferes with the body's ability to fight infection and certain types of cancer. Doctors use blood tests that measure immune function (CD4+ cell count) and the level of virus in the blood (viral load) to monitor patients with HIV-1 infection. As the disease advances, the CD4+ cell count drops and viral loads increase. Doctors treat HIV-1 infection with combinations of different drugs (antiretroviral agents). Combination therapy is difficult because patients need to take many pills several times a day and side effects are common. Doctors and patients wonder about the best time to start combination therapy. Guidelines recommend therapy in patients who have CD4+ cell counts less than 0.200 × 109 cells/L. Whether counts above these levels should guide the timing of therapy is unclear.

Why did the researchers do this particular study?

To see whether CD4+ cell count at the time of starting antiretroviral therapy or refilling drug therapy regularly (adherence) is more closely related to survival.

Who was studied?

1422 HIV-1–infected adults in Canada who began therapy between August 1996 and July 2000.

How was the study done?

CD4+ cell counts were measured before therapy began. Patients were then prescribed triple antiretroviral drug therapy. Drugs were dispensed through one center in British Columbia. The researchers assessed adherence to drugs according to whether patients refilled their prescriptions regularly during their first year of therapy. Patients were followed for 2 to 6 years. The researchers reviewed medical records and government vital statistics data to assess deaths that occurred during this time. The researchers then looked at whether the initial CD4+ cell count level or adherence to therapy best predicted survival.

What did the researchers find?

In general, patients with CD4+ cell counts greater than or equal to 0.200 × 109 cells/L who refilled their drug prescriptions regularly had low death rates. Among these patients, survival was similar regardless of whether therapy was started when counts were 0.200 to 0.349 × 109 cells/L or higher (≥ 0.350 × 109 cells/L). Patients with CD4+ cell counts of 0.200 to 0.349 × 109 cells/L and ≥ 350 × 109 cells/L who did not refill their drug prescriptions regularly had higher death rates than patients who refilled their prescriptions regularly.

What were the limitations of the study?

The study took place in a setting where health care, including drug therapy, was readily available and free. Results may not apply to other settings. Adherence to drug therapy was measured by numbers of dispensed prescriptions. Some patients may have refilled prescriptions regularly yet not have taken all of the prescribed pills. Potential differences in death rates between some groups may have been missed because few patients died.

What are the implications of the study?

Among patients with CD4+ cell counts greater than 0.200 × 109 cells/L, taking antiretroviral therapy regularly is probably more closely related to improved survival than is the CD4+ cell count (0.200 to 0.349 or ≥ 0.350 × 109 cells/L) when therapy is started.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general jounals
BMJ 2010;341:c5893-c1494.

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy This Article

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Register Now for a free account
Advertisement

Related Content

Customize your page view by dragging & repositioning the boxes below.

In the Clinic
Allergic Rhinitis
Ann Intern Med. 2007;146(7):ITC4-1.
Topic Collections
PubMed Articles
Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States.
PharmacoEconomics Issue date: 2013 Apr 26
The NRTIs Lamivudine, Stavudine and Zidovudine Have Reduced HIV-1 Inhibitory Activity in Astrocytes.
PloS one Issue date: 2013

Annals of Internal Medicine

Other Resources

Copyright © 2013 The American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Buy This Article

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Register Now for a free account
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)